- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00042016
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
October 12, 2009 updated by: Astex Pharmaceuticals, Inc.
A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571)
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia chronic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Princess Margaret Hospital
-
-
-
-
California
-
Duarte, California, United States
- City of Hope Medical Center
-
Escondido, California, United States
- Scripps Clinic
-
Los Angeles, California, United States
- USC/Norris Cancer Center
-
-
Minnesota
-
St. Louis Park, Minnesota, United States
- Metro-Minnesota CCOP
-
-
New York
-
Valhalla, New York, United States
- New York Medical College
-
-
South Carolina
-
Columbia, South Carolina, United States
- Liberty Hematology/Oncology
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion:
- Histologically confirmed diagnosis of CML chronic phase
- Ph chromosome-positive
- Previous treatment with imatinib mesylate resulting in: i) Hematologic Resistance / Hematologic Refractory: Based on a physician's (documented) decision to discontinue imatinib mesylate treatment due to failure of continued benefit or no benefit to the patient, ii) Imatinib Mesylate Intolerance: any toxicity resulting in a physician's (documented) decision to discontinue imatinib mesylate treatment.
- Patients must have recovered from the side effects of previous CML therapy for chronic phase with the exception of hydroxyurea
- Age >/= 2 years
- Bilirubin </= 3 x the upper limit of normal (ULN), SGOT and SGPT </= 3 x ULN, except </= 5 x ULN in leukemic involvement of the liver, serum creatinine </= 2 x ULN
- WHO performance status 0-3
- A negative serum hCG pregnancy test in patients of childbearing potential
- Able to give signed informed consent directly or through a parent or guardian for minors
Exclusion:
- Leukemic involvement of the central nervous system
- Active malignancy other than CML or non-melanoma cancer of the skin
- Previous treatment for CML with another investigational agent within 28 days of study entry
- At study entry, patients who were treated with: imatinib mesylate within the past 48 hours; interferon-alpha within the past 48 hours; homoharringtonine within the past 14 days; low-dose cytosine arabinoside within 7 days, moderate dose within 14 days, or high dose within 28 days; etoposide, anthracyclines, or mitoxantrone within 21 days; busulfan within the past six weeks
- Patients who had received hematopoietic stem cell transplantation within 6 weeks of Day 1 decitabine therapy
- Patients with Grade 3/4 cardiac disease or any other serious concurrent medical condition.
- Patients who are pregnant or nursing. All patients of childbearing potential must practice effective methods of contraception while on study.
- Patients with mental illness or other condition precluding their ability to give informed consent or to comply with study requirements
- Patients with systemic, uncontrolled infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Study Registration Dates
First Submitted
July 19, 2002
First Submitted That Met QC Criteria
July 22, 2002
First Posted (Estimate)
July 23, 2002
Study Record Updates
Last Update Posted (Estimate)
October 14, 2009
Last Update Submitted That Met QC Criteria
October 12, 2009
Last Verified
June 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Decitabine
Other Study ID Numbers
- DAC-014
- DACO-014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
M.D. Anderson Cancer CenterNovartisCompletedLeukemia, Myelogenous, ChronicUnited States
-
The University of Hong KongUnknownCessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaLeukemia, Myelogenous, Chronic PhaseHong Kong
-
Assiut UniversityUnknownChronic Phase Chronic Myelogenous Leukemia
Clinical Trials on decitabine (5-aza-2'deoxycytidine)
-
Astex Pharmaceuticals, Inc.Eisai Inc.CompletedChronic Myelogenous LeukemiaUnited States, Canada
-
Astex Pharmaceuticals, Inc.CompletedMyelodysplastic SyndromeUnited States
-
Astex Pharmaceuticals, Inc.Eisai Inc.CompletedChronic Myelogenous LeukemiaUnited States, Canada
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedThalassemiaUnited States, Canada
-
Roswell Park Cancer InstituteWithdrawnCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | PSA...United States
-
M.D. Anderson Cancer CenterEisai Inc.CompletedAcute Lymphocytic LeukemiaUnited States
-
Johnson & Johnson Taiwan LtdCompletedMyelodysplastic SyndromeTaiwan
-
Chinese PLA General HospitalNavy General Hospital, BeijingUnknownRecurrent Adult Acute Myeloid LeukemiaChina
-
National Cancer Institute (NCI)Active, not recruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White CellsUnited States